Phase I Study Of Amg 509, A Steap1 X Cd3 T-Cell Recruiting Xmab 2+1 Immune Therapy, In Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc).

William Kevin Kelly,David William Pook,Leonard Joseph Appleman,David Michael Waterhouse,Lisa Horvath,William Jeffery Edenfield,Nobuaki Matsubara,Daniel Costin Danila,Rahul Raja Aggarwal,Daniel Peter Petrylak,Oliver A. Sartor,Christopher Joseph Sumey,Nabil Adra,Andrew J. Armstrong,Cheng Fu-Chih,Julia Stieglmaier,Hosein Kouros-Mehr,Tanya B. Dorff

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 8|浏览57

暂无评分

摘要

TPS183Background: Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a cell surface antigen that is highly expressed in prostate cancer. AMG 509 is a potent bispecific XmAb 2+1 immu...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要